Scientists from Roswell Park Cancer Institute have reported new mechanisms of action of the novel anticancer agent FL118 and new potential therapeutic targets for the agent, a camptothecin analogue.
In separate studies, researchers from Roswell Park clarify the role of cancer testis antigen in ovarian cancer and report new evidence that certain ligand/receptor interactions influence ovarian cancer prognosis.
Research led by Maciej Goniewicz, PhD, PharmD, of Roswell Park Cancer Institute shows that use of electronic cigarettes among students in Poland has increased dramatically, rising more than threefold in just the last three years.
Researchers at Roswell Park Cancer Institute report that expression of MAGE cancer-testis antigens correlates with clinical outcome in epithelial ovarian cancer, and that several of these unique proteins may prove to be prognostic factors for ovarian cancer.
The New York State Department of Health has granted Roswell Park Cancer Institute (RPCI) approval to begin genomic testing of cancer patients using its OmniSeq TargetTM advanced molecular diagnostic laboratory test, one of only three such tests approved for use in New York State.
BlueCross BlueShield of Western New York has redesignated Roswell Park Cancer Institute as a Blue Distinction Center for delivering quality transplant care as part of the Blue Distinction Centers for Specialty Care program.
A research team led by Irwin H. Gelman, Ph.D., of Roswell Park Cancer Institute has identified a new suppressor of cancer metastasis, FOXO4, that may point the way toward development of more effective treatments for solid tumors.
Researchers at Roswell Park Cancer Institute and the University at Buffalo found that cognitive assessment can effectively measure the expertise of robotic surgeons with varying levels of experience.
Researchers at Roswell Park Cancer Institute have identified a mechanism of breast cancer cells that leads to chemotherapy resistance in inflammatory breast cancer.
Roswell Park Cancer Institute was named a Lead Academic Participating Site (LAPS) within the NCI’s new National Clinical Trials Network and will receive a five-year, $3.08 million grant.
Roswell Park Cancer Institute and the University of Pittsburgh Cancer Institute have awarded six grants totaling $275,000 as part of their joint SPORE project to develop new immune-based therapies for ovarian cancer.
A team led by Maciej Goniewicz of Roswell Park Cancer Institute found that high-voltage electronic cigarettes may expose users to increased levels of toxic chemicals, including formaldehyde and acetaldehyde.
Researchers found that patients with metastatic kidney cancer, even those with chronic renal insufficiency, can benefit from high-dose interleukin-2, showing that more patients than previously thought may be good candidates for the therapy.
Roswell Park Cancer Institute collaborated with biophotonics manufacturer Zenalux Biomedical to produce an enhanced spectrographic system for improved early detection of oral cancers.
More than 30 Roswell Park Cancer Institute investigators will present findings at the AACR Annual Meeting 2014. Highlights include studies on personalized medicine, the role of vegetable intake and vitamin D status in breast cancer, and BMT outcomes.
Roswell Park will present findings from 3 studies of Jasco Pharmaceuticals’s JP_11646 at the AACR Annual Meeting 2014. The results show that the novel PIM inhibitor shows promise for treating pancreatic cancer, bladder cancer and acute leukemias.
Roswell Park Cancer Institute investigators will assess the effectiveness of a novel interstitial photodynamic therapy (I-PDT) approach for treating recurrent head and neck cancers.
New research on dendritic cells from Roswell Park Cancer Institute suggests that manipulating the CD80/CD86 pathway may yield new strategies for treating multiple myeloma.
Writing in the journal Molecular Cell, a team led by Mikhail Nikiforov, PhD, has identified a previously unrecognized feed-forward mechanism of reactive-oxygen-species regulation.
In the largest and most comprehensive study to link secondhand smoke exposure to adverse fetal impacts, researchers report that secondhand smoking may lead to pregnancy loss, including miscarriage, stillbirth and tubal ectopic pregnancy.
Roswell Park team reports that the disabling of two key genes, SSeCKS/AKAP12 and Rb, led to early development of prostate cancer and was also associated with high rates of metastasis to nearby lymph nodes.
In the first whole-genome analysis conducted through the Roswell Park Center for Personalized Medicine, and the second ever in bladder cancer, researchers found two distinct patterns of genetic alteration in tumors and identified a potential target.
Roswell Park has been identified by an international research group as one of 13 “over-performing” U.S. centers offering allogeneic blood and marrow transplants.
A research team from Roswell Park Cancer Institute and the Ocean University of China has published its latest preclinical findings about the promising antitumor agent FL118, reporting new insights about the agent's chemical structure.
Study by Roswell Park's Maciej Goniewicz and colleagues compared emissions from electronic and conventional cigarettes. They found that secondhand exposure to nicotine from e-cigarettes is on average 10 times less than from tobacco smoke.
Roswell Park Institute's Dr. Thomas Schwaab is leading 3 separate clinical studies evaluating novel immunotherapy approaches to treating kidney, bladder and prostate cancers.
Jasco Pharmaceuticals and Roswell Park are sharing research results on use of a novel PIM2 inhibitor to overcome multi-drug resistance at the American Society of Hematology (ASH) Annual Meeting.
The National Cancer Institute’s (NCI) new Provocative Questions research funding program has awarded a prestigious grant to a researcher at Roswell Park Cancer Institute (RPCI) to investigate a promising but neglected or unexplored area of cancer research.
The Facilitates Chromatin Transcription (FACT) complex is expressed at higher levels in tumor cell lines and may be a marker for aggressive cancer, Roswell Park Cancer Institute-led studies show
A new phase I study at Roswell Park Cancer Institute will test the safety and efficacy of a new immunotherapy vaccine for treatment of advanced melanoma.
A team led by Dr. Joseph Skitzki of Roswell Park Cancer Institute has published results of a 9-year retrospective study of 112 patients who underwent cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CS/HIPEC).
Comprehensive cancer center, biopharmaceutical company partner on preclinical testing of agent that has shown promise against solid tumors, blood cancers.
Study of 38,000 blood stem cell transplant recipients, led by Dr. Theresa Hahn of Roswell Park Cancer Institute, shows that survival rates increased significantly over 12 years, and numbers of patients receiving transplants grew dramatically.
Studies by Cleveland BioLabs and Roswell Park Cancer Institute identify the liver as a key mediator of the tissue-protective and anticancer activities of Entolimod, a TLR5 agonist; agent prevented some liver metastases in preclinical analysis.
Partnership between genomics consortium, comprehensive cancer center opens way for research collaborations, sharing of resources.
Roswell Park Cancer Institute study highlights resilience of hepatocellular carcinomas, suggests approaches for overcoming those barriers.
Speaking at a disparities symposium at the American Association for Cancer Research Annual Meeting, Christine Ambrosone, PhD, noted that breastfeeding, vitamin D may help to reduce cancer risk among African-American women.
Targeted therapy may prove effective against colon, head/neck, mesothelioma, ovarian and pancreatic cancers.
Results published in Urology show that first simulation-based robotic surgery training curriculum, Fundamental Skills of Robotic Surgery, appears to be effective way to train surgeons safely, outside operating room.
New facility at Roswell Park Cancer Institute, with support from public, private sectors, will perform whole-genome sequencing for research, clinical applications; leading bioinformatics provider CTG (NASDAQ:CTGX) to serve as technology partner
Researchers from Roswell Park Cancer Institute, the University of California at San Diego and CureFAKtor Pharmaceuticals have published the first evidence that inhibiting focal adhesion kinase with CFAK-Y15 can control the growth of glioblastoma tumors.
Roswell Park-led effort found increased levels of serum glutamate in both primary and metastatic prostate tumors, corresponding to increasing Gleason score
The Roswell Park Alliance Foundation, a not-for-profit that manages all donations made to Roswell Park Cancer Institute (RPCI), recently awarded scientific research grants totaling nearly $800,000 to RPCI scientists and clinicians.
A team led by Fengzhi Li, PhD, assessed the antitumor effects of FL118 in preclinical studies and found that this camptothecin analog generated strong anticancer activity with no apparent toxicity.
Researchers from Roswell Park Cancer Institute and Duke University Medical Center have developed a computational method of identifying "causal" genetic variants that lead to particular diseases, with wide application for genome-wide association studies.
Comprehensive cancer center has launched a digital version of its Roswellness magazine and has optimized its web content for smartphone users.
In study of cooperative-group cancer clinical trials, Roswell Park's Graham Warren, MD, PhD, and colleagues found that less than 30% assessed participants' tobacco use, and none provided cessation support.
In article in New England Journal of Medicine, Dr. Philip L. McCarthy and co-authors report significant time-to-progression benefit as well as survival benefit for patients who took maintenance doses of lenalidomide following stem-cell transplant.
Drug Development Research Professorship, grant will support mentoring in drug development, clinical trial design and regulatory science.
Roswell Park Cancer Institute's Song Yao, PhD, Christine Ambrosone, PhD, and colleagues found that African-American women with a specific genetic variation had half the risk of breast cancer compared to women without it.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right